AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 171 min read$CLOV

Reynoso Jamie L. sold $22K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 4,839 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.53 on 2026-07-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Jul 17, 2026, 9:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The CEO’s open-market sale at a stated price is disclosed as part of a pre-arranged 10b5-1 plan, which generally lowers the informational content versus unscheduled selling.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure suggests limited fundamental implication.

03

What to watch

The filing does not indicate whether other insiders or the company simultaneously made offsetting purchases, nor does it provide context on total insider activity beyond this single transaction.

Relevance 2/10Novelty 4/10Timing: Filed 2026-07-17 after-hours/late session, relevant for next session positioning.

Background

The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments Corp. (CLOV).

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Clover Health CEO Jamie L. Reynoso sold 4,839 shares in an open-market transaction at $4.5300 on 2026-07-17 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider sale, but it is explicitly under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

Minimal read-through to the broader healthcare/Medicare Advantage sector; this is company-specific insider trading disclosure.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations, so traders may discount the signal.

Key entities

  • issuer
    CLOV

    Clover Health Investments Corp. (DE), the company whose CEO filed the Form 4 insider sale.

  • insider
    Reynoso Jamie L.

    CEO, Medicare Advantage, who sold 4,839 shares on 2026-07-17.

Read at source← All news

Related articles

AUG 7
$CLOVMedAI 8/10

Clover Health Investments Q2 Earnings Call Highlights

Clover Health Investments (CLOV) reported Q2 adjusted EBITDA of $41 million and GAAP net income of $28 million. For the first half of 2026, it posted $81 million adjusted EBITDA and $55 million GAAP net income, with $443 million cash and investments and no debt. The company raised 2026 guidance to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA, and discussed cohort maturation and 4.5-star ratings for 2027.

yahoo.com6 min
AUG 6
$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.

insurancebusinessmag.com9 min
AUG 5
$CLOVHighAI 9/10

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV): Results of Operations and Financial Condition

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26exx991xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Clover Health Reports Second Quarter 2026 Results Business Highlights: • Delivered strong second quarter 2026 GAAP Net Income alongside continued market-leading Medicare Advantage membership growth • Improved

SEC EDGAR 8-K6 min
JUL 24
$CLOVMed

What's Fueling Clover Health's Recent Stock Surge

Clover Health (CLOV) shares rose about 7% to $2.39 after UnitedHealth Group (UNH) reported strong Q1 2026 results and raised its full-year adjusted net earnings outlook to over $18.25 per share, lifting sentiment for health insurers. Clover also cited 53% YoY Medicare Advantage membership growth and reiterated 2026 GAAP net income profitability guidance. Analysts maintain a Hold rating and a $2.90 average target.

kavout.com4 min